RYZNEUTA

This brand name is authorized in United States. It is also authorized in Austria, Estonia, Italy, Lithuania.

Active ingredients

The drug RYZNEUTA contains one active pharmaceutical ingredient (API):

1	Efbemalenograstim alfa UNII 5UPW5HJW3O - EFBEMALENOGRASTIM ALFA
	Human granulocyte-colony stimulating factor (G-CSF) is a glycoprotein, which regulates the production and release of neutrophils from the bone marrow. Efbemalenograstim alfa is a recombinant fusion protein containing G-CSF, a 16 amino-acid linker, and the Fc portion of human IgG2. Efbemalenograstim alfa is a sustained duration form of G-CSF due to decreased renal clearance. Efbemalenograstim alfa and other G-CSFs have identical modes of action, causing a marked increase in peripheral blood neutrophil counts within 24 hours, with minor increases in monocytes and/or lymphocytes.
	Read more about Efbemalenograstim alfa

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
RYZNEUTA Solution for injection	MPI, US: SPL/PLR	FDA, National Drug Code (US)
RYZNEUTA Solution for injection	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L03AA18		L Antineoplastic and immunomodulating agents → L03 Immunostimulants → L03A Immunostimulants → L03AA Colony stimulating factors
Discover more medicines within L03AA18

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	3066881
IT	Agenzia del Farmaco	051171015
LT	Valstybinė vaistų kontrolės tarnyba	1099363
US	FDA, National Drug Code	73491-627